|
|
|
|
|
Dorzolamide
drug data and news
Dorzolamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Dorzolamide | ||
| Brand Names/Synonyms | CHEMBANK1829; Dorzolamide; Trusopt | ||
| Indication | For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Dorzolamide is topical carbonic anhydrase inhibitor. Dorzolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. | ||
| Mechanism Of Action | Dorzolamide is a sulfonamide and a human carbonic anhydrase II inhibitor. Inhibition of carbonic anhydrase II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. | ||
| Dorzolamide News (When available) |
Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ... Jan 31, 2006 Merck Announces New Unisured Discount Program Targeted to More ... Oct 7, 2005 Equine Glaucoma Sep 22, 2005 Advisory Committee Conference Room Jun 23, 2005 Advisory Committee Conference Room Jun 23, 2005 Merck Announces New Uninsured Discount Program Targeted to More ... Apr 19, 2005 | ||
| Dosage Forms | Solution | ||
| Drug_Category | Antihypertensive Agents; Carbonic Anhydrase Inhibitors; ATC:S01EC03 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Dorzolamide: Although acid-base and electrolyte disturbances were not reported in the clinical trials with TRUSOPT, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving TRUSOPT. | ||
| Toxicity | Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-ethylamino-4-methyl-5,5-dioxo-5$l^{6},7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide | ||
| Chemical Formula | C10H16N2O4S3 | ||
| Molecular Weight | 324.443 g/mol | ||
| Smiles String | CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C | ||
| Melting Point | 283-285 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 0.548 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 4 months | ||
| Protein Binding [%] | ~33% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Dorzolamide.html http://www.rxlist.com/cgi/generic2/dorzol.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00577 | ||
| CAS Registry Number | 120279-96-1 | ||
| KEGG Compound ID | C06969 | ||
| PubChem ID | SID:9183 | ||
| PharmGKB ID | PA449399 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2216205 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |